NCT03059134 is a Phase 3 clinical trial of Mirabegron 25mg in Urinary Incontinence, sponsored by Buddhist Tzu Chi General Hospital.

Who is sponsoring NCT03059134?

NCT03059134 is sponsored by Buddhist Tzu Chi General Hospital.

What drugs are being tested in NCT03059134?

Interventions in NCT03059134: Mirabegron 25mg.

What condition does NCT03059134 study?

NCT03059134 studies Urinary Incontinence, Overactive Bladder Syndrome.

Is NCT03059134 still recruiting?

NCT03059134 is currently completed. Last updated 23 February 2017.

Last reviewed 2017-02-23 · How we verify

NCT03059134

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Completed Phase 3 Last updated 23 February 2017

What this trial tests

Phase 3 trial testing Mirabegron 25mg in Urinary Incontinence in 168 participants. Completed in 27 April 2016.

Timeline

28 April 2015

Primary endpoint
27 April 2016

27 April 2016

Quick facts

Lead sponsor	Buddhist Tzu Chi General Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	168
Start date	28 April 2015
Primary completion	27 April 2016
Estimated completion	27 April 2016

Drugs / interventions tested

Mirabegron 25mg — full drug profile →

Conditions studied

Urinary Incontinence — all drugs for Urinary Incontinence →
Overactive Bladder Syndrome — all drugs for Overactive Bladder Syndrome →

Sponsor

Buddhist Tzu Chi General Hospital

Who can join

18 and older, any sex, with Urinary Incontinence or Overactive Bladder Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and antimuscarinics. Methods: This is a prospective randomized study. OAB patients received mirabegron 25 mg (M25) daily for one month (1M) and then were randomized as group 1: to continue M25, group 2: to mirabegron 50 mg, group 3: to shift to solifenacin 5 mg (S5) and group 4: to combine M25 and S5 for further 2 months (totally 3 months, 3M). Efficacy and AEs were evaluated. At the end of 3M, the preferred option for future treatment was investigated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients.
Kuo YC, Kuo HC. · · 2023 · cited 7× · PMID 36866344 · DOI 10.4103/tcmj.tcmj_209_21

Verify or expand the search:

Other trials of Mirabegron 25mg

Trials testing the same drug.

NCT07114640 — The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Func · Phase 3 · not yet recruiting
NCT05040984 — Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome · unknown
NCT03695822 — Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndro · Phase 4 · withdrawn
NCT03558919 — Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder · Phase 4 · completed
NCT04550702 — Predictors for Retreatement of OAB After DC Mirabegron · completed

Other recruiting trials for Urinary Incontinence

Currently open trials in the same condition.

NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
NCT07105150 — Efficacy of a Video-Based Educational Program on Female Urinary Incontinence · NA · recruiting
NCT07426861 — Pre-Operative Nurse-Led Education With Direct Physiotherapy Referral to Reduce Post-Prostatectomy Incontinence · NA · recruiting
NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting

Other Buddhist Tzu Chi General Hospital trials

Trials by the same sponsor.

NCT06141902 — The Effects of Jing Si Herbal Tea on Physical and Psychological Symptoms in Peripheral Blood Hematopoietic Stem Cell Don · NA · enrolling by invitation
NCT06818526 — Huandao Conditioning Application for Allergic Rhinitis Treatment · NA · not yet recruiting
NCT06744478 — Assessing the Magnitude of Anisometropia in Patients Wearing Misight 1 Day Contact Lens · enrolling by invitation
NCT07287657 — Exploring the Effects of Transcutaneous Electrical Acupoint Stimulation Therapy on Patients After Video-Assisted Thoraco · NA · enrolling by invitation
NCT07334938 — Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Ca · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03059134 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Buddhist Tzu Chi General Hospital
Last refreshed: 23 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03059134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing